## **European Statistical Meeting on Decision Making in Drug Development**



## Suresnes (Paris), Wednesday 12th December 2018

08:45-09:15 09:15-09:30	
	Morning Sessions (Chair: Gaëlle Saint-Hilary)
09:30-10:20	Anthony O'Hagan (University of Sheffield)
	Introduction to decision-making
10:20-11:10	Juan Abellan (GSK)
	Prior elicitation to support quantitative decision-making
11:10-11:30	Break
11:30-12:20	Maria Costa (Novartis)
	Benefit-Risk Assessment in Drug Development
12:20-13:30	Lunch and Poster Session
	Afternoon Sessions (Chair: Guido Thömmes)
13:30-14:20	Paul Frewer (Astra Zeneca)
	Decision Making in Early Clinical Development: The framework
	used within AstraZeneca
14:20-15:10	Nigel Stallard (University of Warwick)
	Decision-making in phase II/III trials using early endpoint data
15:10-15:30	Break
15:30-16:20	Tom Parke (Berry consultants)
	Using simulations to optimize drug development decision-making
16:20-16:30	Closing